A structured search reveals that online marketing of stem-cell-based interventions is skewed
toward developed economies including the United States, Ireland, Australia, and Germany.
Websites made broad, imprecise therapeutic claims and frequently failed to detail
procedures. Widespread marketing poses challenges to regulators, bioethicists, and those
seeking realistic hope from therapies.